Future for biological therapy for uveitis

Current Opinion in Ophthalmology

Volumn 21, Issue 6, 2010, Pages 473-477

  Rosenbaum, James T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

accessory molecules; adhesion molecules; biologics; tumor necrosis factor; uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALPHA INTERFERON; CD52 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE MARKER; DACLIZUMAB; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 6; NATALIZUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; VASCULOTROPIN;

BEHCET DISEASE; BIOLOGICAL THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; EYE INFLAMMATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UVEITIS;

BIOLOGICAL THERAPY; HUMANS; UVEITIS;

EID: 78049287217     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833f00b3     Document Type: Review

References (45)

1. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006; 113:2137-2323.
2. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358:295-296.
3. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-1368.
4. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123:903-912.
5. Suhler EB, Smith JR, Wertheim MS, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009; 127:819-822.
6. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91:319-324.
7. Braun J, Baraliakos X, Listing J, Seiper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the antitumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52:2447-2451.
8. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009; 68:696-701.
9. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59:996-1001.
10. Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006; 14:145-150.
11. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56:3248-3252.
12. Sicotte NL, Voskuh RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57:1885-1888.
13. Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117:1612-1616.
14. Giganti M, Beer PM, Lemanski N, et al. Adverse events after intravitreal infliximab (Remicade). Retina 2010; 30:71-80.
15. Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007; 39:184-186.
16. Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol 2008; 18:306-308.
17. Kurz P, Suhler EB, Choi D, Rosenbaum JT. Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol 2009; 93:546-548.
18. Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60:1540-1547.
19. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009; 60:3225-3228.
20. Giuliari GP, Hinkle DM, Foster CS. Local treatment for lymphoid malignancies of the eye. Anticancer Agents Med Chem 2009; 9:1123-1128.
21. Isaacs JD, Hale G, Waldmann H, et al. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol 1054-; 79:5.
22. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786-1801.
23. Cervantes-Castaneda R, Giuliari G, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 2009; 19:622-629.
24. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148:303e2-309e2.
25. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-TNFalpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010; 62:821-825.
26. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2:619-626.
27. Chaudhuri A, Behan PO. Natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:1598-1599.
28. Bennett JL. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol Res 2006; 28:291-298.
29. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159:274-285.
30. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684.
31. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-640.
32. Segal BM, Constantinescu CS, Raychouduri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7:796-804.
33. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-1463.
34. Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205:799-810.
35. Zhang Z, Zhong W, Spencer D, et al. Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11. 10 mice. Cytokine 2009; 46:79-91.
36. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-898.
37. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized antiinterleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62:929-939.
38. Webster AC, Ruster LP, McGee, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010:CD003897.
39. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-TacmAb: aphaseI/II clinical trial. Proc Natl Acad Sci U S A 1999; 96:7462-7466.
40. Papaliodis GN, Chu D, Foster CS, et al. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003; 110:786-789.
41. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87:423-431.
42. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607-612.
43. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028.
44. Ottiger M, Thiel MA, Feige U, et al. Efficient intraocular penetration of topical anti-TNF-{alpha} single-chain antibody (ESBA 105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 2008; 50:779-786.
45. Lichtlen PD, Lam T, Nork M, et al. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing efficacy of bevacizumab, adalimumab and ESBA105. Invest Ophthalmol Vis Sci 2010. [Epub ahead of print]